PatriciaJGiardinaMD
Pediatric Hematology & Oncology • New York, NYClinical Professor of Pediatrics, Cornell Univ-Weill Medical College
Are you Dr. Giardina?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 39 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
525 E 68th St
# P-695
New York, NY 10065Phone+1 212-746-3400Fax+1 212-746-3892
Summary
- Dr. Patricia Giardina, MD is a pediatric hematologist/oncologist in New York, New York. She is currently licensed to practice medicine in New York. She is affiliated with New York-Presbyterian Hospital and is a Clinical Professor of Pediatrics at Cornell Univ-Weill Medical College.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 1969 - 1971
Zucker School of Medicine at Hofstra/Northwell at Cohen Children's Medical CenterInternship, Pediatrics, 1968 - 1969
New York Medical CollegeClass of 1968- New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology
Certifications & Licensure
NY State Medical License 1970 - 2025- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Start of enrollment: 2000 Jul 01
- Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases Start of enrollment: 2005 Jun 01
- Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both Start of enrollment: 2008 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 233 citationsEffectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trialEric Nisbet-Brown, Nancy F. Olivieri, Patricia J. Giardina, Robert W. Grady, Ellis J. Neufeld
Lancet. 2003-05-10 - 504 citationsA phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.Maria Domenica Cappellini, Alan R. Cohen, Antonio Piga, Mohamed Bejaoui, Silverio Perrotta
Blood. 2006-05-01 - 700 citationsLinkage of β-thalassaemia mutations and β-globin gene polymorphisms with DNA polymorphisms in human β-globin gene clusterStuart H. Orkin, Haig H. Kazazian, Stylianos E. Antonarakis, Sabra C. Goff, Corinne D. Boehm
Nature. 1982-04-15
Grant Support
- Prevention Of Complications Of ThalassemiaCenters For Disease Control And Prevention2007–2011
- Thalassemia Clinical Research NetworkNational Heart, Lung, And Blood Institute2005–2009
- Desferrioxamine Therapy In Iron OverloadNational Center For Research Resources2005–2007
- Thalassemia Clinical Research Network Cross-Sectional Study Of OsteoporosisNational Center For Research Resources2005
- New York Region Thalassemia CenterNational Heart, Lung, And Blood Institute2000–2004
- Dmhp(Deferiprone)--An Oral Iron Chelation Agent For ThalassemiaNational Center For Research Resources1998–2002
- A Comprehensive Study Of Clinically Staged Pediatric Hodgkin'S DiseaseNational Center For Research Resources1998–2002
- Desferrioxamine Therapy In Iron OverloadNational Center For Research Resources1996–2002
- Stimulation Of Fetal HB Synthesis In Thalassemia &Ss Disease By SPBNational Center For Research Resources1996
